Scarica l'app Stockscreener
0.8659
3.32%
0.0278
Dopo l'orario di chiusura:
.87
0.0041
+0.47%
Precedente Chiudi:
$0.8381
Aprire:
$0.82
Volume 24 ore:
165.88K
Relative Volume:
1.16
Capitalizzazione di mercato:
$44.98M
Reddito:
-
Utile/perdita netta:
$-51.47M
Rapporto P/E:
-0.8659
EPS:
-1
Flusso di cassa netto:
$-47.50M
1 W Prestazione:
-1.90%
1M Prestazione:
-13.41%
6M Prestazione:
-46.22%
1 anno Prestazione:
-59.73%
Intervallo 1D:
$0.81
$0.88
Intervallo di 1 settimana:
$0.81
$0.91
Portata 52W:
$0.81
$2.215
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Nome
Pmv Pharmaceuticals Inc
Settore
Industria
Telefono
(609) 642-6670
Indirizzo
400 ALEXANDER PARK DRIVE, PRINCETON
Confronta PMVP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
0.8659 | 45.86M | 0 | -51.47M | -47.50M | -1.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Iniziato | Craig Hallum | Buy |
| 2024-04-12 | Iniziato | Jefferies | Buy |
| 2023-12-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-19 | Iniziato | Oppenheimer | Perform |
| 2021-08-02 | Iniziato | Guggenheim | Buy |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Cowen | Outperform |
| 2020-10-20 | Iniziato | Evercore ISI | Outperform |
| 2020-10-20 | Iniziato | Goldman | Neutral |
Mostra tutto
Pmv Pharmaceuticals Inc Borsa (PMVP) Ultime notizie
PMVP Advances PYNNACLE Trial with Steady Enrollment | PMVP Stock News - GuruFocus
PMV Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
PMVP Reports First Quarter Cash Position and Operational Spendin - GuruFocus
Randy A. Bowman Appointed Chairman of the Board at Westwood Holdings Group - The Manila Times
PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results - Nasdaq
JPMorgan Chase & Co. Buys 23,559 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
In the Green: PMV Pharmaceuticals Inc (PMVP) Closes at 0.87, Up/Down -7.34 from Previous Day - DWinneX
PMV Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Sells 11,052 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.32 - MSN
ConocoPhillips (NYSE:COP) Receives Average Recommendation of “Buy” from Analysts - American Banking and Market News
APA Group (OTCMKTS:APAJF) Stock Price Down 9.1% – Here’s What Happened - Defense World
XP Power (OTCMKTS:XPPLF) Trading Down 12% – Should You Sell? - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% – Should You Sell? - Defense World
Dunxin Financial (NYSEAMERICAN:DXF) Stock Price Up 5.6% – Here’s What Happened - Defense World
Molecular Partners (OTCMKTS:MLLCF) Shares Down 1.4% – Should You Sell? - Defense World
PMV Pharmaceuticals patents new TP53 stabilizers - BioWorld MedTech
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors - Business Wire
Promising Biotech Stocks To Watch Now – April 6th - Defense World
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
3 US Penny Stocks To Consider In February 2025 - simplywall.st
PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
Pmv Pharmaceuticals Inc Azioni (PMVP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):